UK Markets closed

NVO Jan 2024 175.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
20.700.00 (0.00%)
As of 11:29AM EST. Market open.
Full screen
Loading interactive chart…
  • Zacks

    Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study

    After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.

  • Motley Fool

    Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

    On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not be advancing into late-stage clinical trials. Now, the company's bid to capture portions of the extremely lucrative type 2 diabetes and obesity drug markets looks like it's in trouble.

  • Motley Fool

    Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

    Novo Nordisk (NYSE: NVO) is a leader in the billion-dollar weight loss market, with two drugs that have helped its earnings soar. The company sells semaglutide under the name Wegovy for weight loss and as Ozempic for type 2 diabetes. Doctors also have prescribed rival Eli Lilly's (NYSE: LLY) diabetes drug, Mounjaro, for weight management, causing sales at this big pharma to take off, too.